Antony Burton
Associate Director, Chemical Biology & Proteomics Dunad Therapeutics
Seminars
Thursday 5th February 2026
Chemoproteomics-Based Discovery of CNS-Penetrant Covalent Inhibitors
10:30 am
- Effectively utilizing chemoproteomic platforms to triage hits and facilitate efficient hit-to-lead development
- Conducting high-throughput screening in physiological conditions to streamline translation
- Data to exemplify how chemoproteomics has enabled the detection and optimization of clinically successful therapeutic candidates
